Phaseline

Companies › PharmaMar

PharmaMar: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 3; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Lurbinectedin
Alkylating agent that binds to DNA and causes strand breaks
DCXRPhase 3LeiomyosarcomaAug 2029
PM54–Phase 1Advanced Solid Tumor; Advanced MalignanciesDec 2026
PM534–Phase 1Patients With Advanced Solid Tumors–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05835609PM534Phase 1Patients With Advanced Solid TumorsOncologyOct 2026
NCT05841563PM54Phase 1Advanced Solid TumorOncologyDec 2026
NCT07644039PM54Phase 1Advanced MalignanciesOncologyApr 2029
NCT06088290LurbinectedinPhase 3LeiomyosarcomaOncologyAug 2029

Targets

DCXR (1)

Companies with the same targets

–

Companies built like this

RayzeBio Nuvalent Day One Biopharmaceuticals InxMed (Shanghai) SystImmune

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.